Metformin
- Generic Name
- Metformin
- Brand Names
- Actoplus Met, Avandamet, Fortamet, Glucophage, Glucovance, Glumetza, Glycon, Invokamet, Janumet, Jentadueto, Kazano, Kombiglyze, Komboglyze, Qternmet, Riomet, Segluromet, Synjardy, Trijardy, Velmetia, Xigduo
- Drug Type
- Small Molecule
- Chemical Formula
- C4H11N5
- CAS Number
- 657-24-9
- Unique Ingredient Identifier
- 9100L32L2N
- Background
Metformin is a biguanide antihyperglycemic agent and first-line pharmacotherapy used in the management of type II diabetes.
Metformin is considered an antihyperglycemic drug because it lowers blood glucose concentrations in type II diabetes without causing hypoglycemia. It is commonly described as an "insulin sensitizer", leading to a decrease in insulin resistance and a clinically significant reduction of plasma fasting insulin levels. Another well-known benefit of this drug is modest weight loss, making it an effective choice for obese patients type II diabetes.
Metformin was first approved in Canada in 1972, and received subsequent FDA approval in the US in 1995.
- Indication
Metformin immediate-release formulations
Metformin is indicated as an adjunct to diet and exercise to improve glycemic control in adults and pediatric patients ≥10 years old with type 2 diabetes mellitus.
Metformin extended-release tablet (XR)
The extended-release formulation of metformin is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. Safety in children has not been determined to this date.
Metformin combination products
Metformin is a component of a variety of combination products with other anti-diabetic agents. It is indicated, along with diet and exercise, to improve glycemic control in adult patients with type 2 diabetes mellitus in combination with DPP-4 inhibitors (sitagliptin, linagliptin, alogliptin, or saxagliptin), in combination with SGLT2 inhibitors (canagliflozin, empagliflozin, ertugliflozin, or dapagliflozin), or in combination with pioglitazone.
- Associated Conditions
- Cardiovascular Mortality, End Stage Renal Disease (ESRD), Hospitalizations, Polycystic Ovarian Syndrome (PCOS), Type 2 Diabetes Mellitus, Decreased estimated glomerular filtration rate
- Associated Therapies
- -
Clinical and Biologic Effects of Metformin in Early Stage Breast Cancer
- First Posted Date
- 2009-05-12
- Last Posted Date
- 2012-01-19
- Lead Sponsor
- Mount Sinai Hospital, Canada
- Target Recruit Count
- 39
- Registration Number
- NCT00897884
- Locations
- 🇨🇦
Princess Margaret Hospital, Toronto, Ontario, Canada
🇨🇦Mount Sinai Hospital, Toronto, Ontario, Canada
Hypothalamic Obesity Following Craniopharyngioma Surgery: A Pilot Trial of Combined Metformin and Diazoxide Therapy
- First Posted Date
- 2009-05-04
- Last Posted Date
- 2017-11-17
- Lead Sponsor
- The Hospital for Sick Children
- Target Recruit Count
- 9
- Registration Number
- NCT00892073
- Locations
- 🇨🇦
The Hospital for Sick Children, Toronto, Ontario, Canada
Sitagliptin (MK-0431) vs. Placebo in Patients With Inadequate Glycemic Control on Metformin With Pioglitazone (MK-0431-128)
- Conditions
- Interventions
- First Posted Date
- 2009-04-21
- Last Posted Date
- 2017-05-23
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 313
- Registration Number
- NCT00885352
Metformin and Gestational Diabetes in High-risk Patients: a RCTs
- Conditions
- Interventions
- First Posted Date
- 2009-04-17
- Last Posted Date
- 2013-04-08
- Lead Sponsor
- University Magna Graecia
- Target Recruit Count
- 80
- Registration Number
- NCT00883259
- Locations
- 🇮🇹
Pugliese Hospital, Catanzaro, Catanzaro, CZ, Italy
🇮🇹"Pugliese" Hospital, Catanzaro, Italy
🇮🇹University of Catanzaro, Italy, Catanzaro, Italy
A Study of Pre-operative Metformin in Prostate Cancer
- First Posted Date
- 2009-04-15
- Last Posted Date
- 2012-06-19
- Lead Sponsor
- University Health Network, Toronto
- Target Recruit Count
- 24
- Registration Number
- NCT00881725
- Locations
- 🇨🇦
University Health Network, Toronto, Ontario, Canada
Empagliflozin (BI 10773) in Type Two Diabetes (T2D) Patients, Open Label Extension
- Conditions
- Interventions
- First Posted Date
- 2009-04-15
- Last Posted Date
- 2014-06-16
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 660
- Registration Number
- NCT00881530
- Locations
- 🇺🇸
1245.24.101006 Boehringer Ingelheim Investigational Site, Wadsworth, Ohio, United States
🇺🇸1245.24.101024 Boehringer Ingelheim Investigational Site, St. Cloud, Florida, United States
🇺🇸1245.24.101015 Boehringer Ingelheim Investigational Site, Dallas, Texas, United States
A Comparison of SLx-4090 in Combination With Metformin Versus Metformin Therapy Alone in Patients With Type 2 Diabetes
- First Posted Date
- 2009-03-30
- Last Posted Date
- 2023-11-18
- Lead Sponsor
- Response Pharmaceuticals
- Target Recruit Count
- 82
- Registration Number
- NCT00871936
A Study of the Safety and Efficacy of MK-3577 in Participants With Type 2 Diabetes Mellitus (MK-3577-009)
- Conditions
- Interventions
- First Posted Date
- 2009-03-25
- Last Posted Date
- 2018-09-10
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 118
- Registration Number
- NCT00868790
Efficacy and Long-Term Safety of Vildagliptin as Add-on Therapy to Metformin in Patients With Type 2 Diabetes
- Conditions
- Interventions
- First Posted Date
- 2009-03-12
- Last Posted Date
- 2020-12-29
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 1988
- Registration Number
- NCT00860288
- Locations
- 🇰🇷
Ajou university hospital, Suwon, Korea, Republic of
🇱🇻Daugavpils Regional Hospital, Daugavpils, Latvia
🇱🇻Talsi Clinical Hospital, Talsi, Latvia
Insulin Glargine First Line vs Metformin in Type 2 Diabetic Subjects
- First Posted Date
- 2009-03-09
- Last Posted Date
- 2012-01-11
- Lead Sponsor
- GWT-TUD GmbH
- Target Recruit Count
- 96
- Registration Number
- NCT00857870
- Locations
- 🇩🇪
GWT -TUD, Center for Clinical Studies, Dresden, Germany
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.